Lupin has entered into a Licensing and Supply Agreement with Zydus Lifesciences to expand access to innovative Semaglutide Injection (15 mg/3 ml) with a patient-friendly reusable pen device in India. This partnership brings together Lupin’s extensive reach in the Indian market and Zydus’ robust development capabilities, driven by the shared objective of bringing advanced therapies for metabolic disorders.

Under this agreement, Lupin will have semi-exclusive rights to co-market Zydus’ innovative Semaglutide Injection in India under the brand names Semanext and Lupin’s Livarise. Zydus will continue to market the product under the brand names SEMAGLYN, MASHEMA and ALTERME. As part of the agreement, Lupin will pay Zydus upfront licensing fees and milestone payments on achieving pre-defined milestones.  

Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.